link to RWJMS home page
Banner Image Here

Current Clinical Trials



Invitation for a Treatment Trial for Autism

Dr. Sherie Novotny of the Department of Psychiatry at Rutgers-RWJMS and collaborators are starting a treatment trial to see whether DHA, the major omega-3 fatty acid found in the brain and a part of fish oil, has any effects on the symptoms of autism.

The trial will be a 12-week clinical study with children or adolescents between ages 5 and 17 with a diagnosis of Autism Spectrum Disorder. This trial will also study genes related to DHA, as well as chemicals related to DHA in the urine.

If you are interested in finding out more about this study, please contact Dr. Novotny’s study coordinator, Dr. Rakhee Wasiulla, who will ask you a few questions to see if your child or adolescent is eligible for the study. Based upon these questions, some of the families will be invited to participate in the study. In addition to the DHA treatment, a small blood sample will be drawn at the beginning of the project, and urine samples will be taken at the beginning and end of the treatment.


Rakhee Wasiulla, Ph.D.
Study Coordinator
Rutgers-Robert Wood Johnson Medical School
Department of Psychiatry
671 Hoes Lane West
Piscataway, NJ 08854

Phone: 732 235 5690
Fax: 732 235 3923


Biofeedback For Adults With Persistent Asthma

Our practice is participating in a research study for which you may be eligible.  It is funded by a grant from the National Institutes of Health, and will test new non-drug treatments for asthma.  The treatments involve using a small biofeedback device that helps teach you to control your own body. You also will receive education about asthma and how to care for it. The study is intended for people with mild or moderate asthma who are not currently taking inhaled steroid medications.  Eligible patients will be randomly assigned to one of two biofeedback conditions. One of these may be more effective than the other.

People who participate in the study will have their asthma severity assessed and receive free asthma care for the duration of their study participation, at no cost. Participants can be reimbursed up to $535, at the completion of the study, with funds provided by the National Institute of Health. Asthma severity will be assessed 2 times, at the beginning and at the end of your participation. Other measures of asthma will be taken on three occasions, at the beginning, middle, and end of participation, and participants will be asked to take some simple daily measures at home (taking 5-10 minutes per day).  Those who participate in the study will be lent a machine to use at home during the study.  The study will require 18 visits over approximately 4 months. Participants will be paid for all visits. Although we are evaluating a nondrug treatment, some subjects will receive standard asthma medication (inhaled steroids) for about 1 month.

Principal Investigator:  Paul Lehrer, PhD

Trial Objective: We are testing two different non-medication biofeedback treatments for adults with persistent asthma who are not taking inhaled steroid medication.

Enrollment: Active Clinical Trials Currently Recruiting

How to Participate: Your participation in the study will include no cost asthma evaluations, detailed action plans, and reimbursement for your time. Some participants may also receive free standard asthma medication. For more information, please contact Milisyaris Aviles at 732-235-3919, or email